

Name	Mira Hleyhel
Educational Background	<p>PhD in Public health: Epidemiology and Biomedical Information Sciences, 2014, Université Paris VI, Paris.</p> <p>Master's in research Methods in Environment and Health, 2011, Joseph Fourier University, Grenoble.</p> <p>Doctor of Pharmacy (PharmD), 2009, Lebanese University, Hadath.</p>
Summary of career to date (150 -250 words)	<p>Mira Hleyhel is a doctor in Pharmacy and is currently a part time instructor in the Faculty of Public Health at the Lebanese University and the Faculty of Health Sciences at the University of Balamand where she is teaching and conducting research. Mira completed her PhD in Public Health in September 2014 at Université Paris VI. After the completion of her doctoral studies, Mira continued her training as a postdoctoral researcher at the National Institute for Health and Medical Research (INSERM). Since 2014, Mira has taught varied courses in public health including epidemiology, biostatistics, methodology of research and methodology of clinical trials, and provided guidance and supervision to students.</p> <p>In addition to teaching, her research interests included topics related to infectious diseases such as human immunodeficiency virus, human papillomavirus, and Coronavirus disease 2019 and to rational use of medicines such as the rational use of antibiotics and dietary supplements use. Mira has also supervised more than 10 student research projects which have resulted in several publications in peer-reviewed scientific journals.</p>
Research interests and specialty (List up to 5)	<ul style="list-style-type: none"> <li>- Infectious diseases</li> <li>- Rational use of medicines</li> </ul>
List of publications (Preferable)	<ul style="list-style-type: none"> <li>- <b>Hleyhel M*</b>, Haddad C*, Haidar N, Charbachy M, Saleh N. Determinants of knowledge and prevention measures towards COVID-19 pandemic among Lebanese dentists: a cross sectional survey. BMC Oral Health. 2021 May 6;21(1):241.</li> <li>- Youssef L, Hallit S, Sacre H, Salameh P, Cherfan M, Akel M, <b>Hleyhel M</b>. Knowledge, Attitudes and Practices towards People Living with HIV/AIDS in Lebanon. Plos one. 2021 Mar 25;16(3):e0249025.</li> <li>- Lahoud N, Rizk R, <b>Hleyhel M</b>, Baaklini M, Zeidan RK, Ajaka N, Rahme D, Maison P, Saleh N, Trends in the Consumption of Antibiotics in the Lebanese Community Between 2004 and 2016. Int J Clin Pharm. 2021 Jan. Epub ahead of print.</li> <li>- Grabar S, <b>Hleyhel M</b>, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, Pradier C, Salmon D, Simon A, Pourcher V, Spano JP, Poizot-Martin I, Costagliola D. Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH)—Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study. HIV med. 2019 Mar; 20(3):222-229</li> </ul>

- Ghaddar F, Salameh P, Saleh N, Farhat F, Chahine R, Lahoud N, **Hleyhel M**, Zeidan RK. Noncardiac Lebanese hospitalized adult patients' awareness of their coronary artery disease risk factors. Vasc Health Risk Manag. 2018 Nov; 14:371-382.
  
- **Hleyhel M**, Goujon S, Sibiude J, Tubiana R, Dollfus C, Faye A, Mandelbrot L, Clavel J, Warszawski J, Blanche S; ANRS French Perinatal Cohort study Group. Risk of cancer in children exposed to antiretroviral nucleoside analogues in utero: The french experience. Environ Mol Mutagen. 2017 Dec. [Epub ahead of print].
  
- **Hleyhel M**, Goujon S, Sibiude J, Blanche S, Warszawski J; on behalf the ANRS French Perinatal Cohort study Group. In utero exposure to nelfinavir-ethyl methyl sulfone. AIDS. 2016 Nov; 30(17):2729-2730.
  
- **Hleyhel M**, Goujon S, Delteil C, Vasiljevic A, Luzzi S, Stephan JL, Reliquet V, Jannier S, Tubiana R, Dollfus C, Faye A, Mandelbrot L, Clavel J, Warszawski J, Blanche S; on behalf the ANRS French Perinatal Cohort study Group. Risk of cancer in children exposed to didanosine in utero. AIDS. 2016 May; 30(8):1245-56.
  
- **Hleyhel M**, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; FHDH-ANRS CO4. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Int J Cancer. 2015 Nov; 137(10): 2443-53.
  
- **Hleyhel M**, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4). Risk of non-AIDS-
- defining cancers among HIV-1-infected individuals in France between 1997 and 2009: Results from a French cohort. AIDS. 2014 Sept; 28(14): 2109-2118.
  
- **Hleyhel M**, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Costagliola D, Grabar S; on behalf of the FHDH-ANRS CO4 cohort. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: Results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2013 Dec; 57(11):1638-47.